Status:
COMPLETED
Evaluating Atorvastatin With Omega-3 Fatty Acids in Cardiovascular Risk Reduction in Patients With Type 2 Diabetes
Lead Sponsor:
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Collaborating Sponsors:
Churchill Hospital
Conditions:
Diabetes, Type 2
Eligibility:
All Genders
18+ years
Phase:
PHASE4
Brief Summary
The AFORRD trial is asking three important questions: What proportion of people with Type 2 Diabetes are likely to be treated satisfactorily with a fixed dose of a statin that lowers blood cholestero...
Eligibility Criteria
Inclusion
- They have a diagnosis of Type 2 Diabetes Mellitus for at least 3 months prior to entry.
- Are not known to have had a cardiovascular event
Exclusion
- They are taking prescribed lipid lowering therapy
- Have triglycerides \> or = 8.0 mmol/L
Key Trial Info
Start Date :
November 1 2004
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
July 1 2006
Estimated Enrollment :
810 Patients enrolled
Trial Details
Trial ID
NCT00141232
Start Date
November 1 2004
End Date
July 1 2006
Last Update
February 18 2021
Active Locations (59)
Enter a location and click search to find clinical trials sorted by distance.
1
Pfizer Investigational Site
Irvine, Ayrshire, United Kingdom, KA12 OAY
2
Pfizer Investigational Site
Farnworth, Bolton, United Kingdom, BL4 9AH
3
Pfizer Investigational Site
Thornhill, Cardiff, United Kingdom, CF14 9BB
4
Pfizer Investigational Site
Fowey, Cornwall, United Kingdom, PL23 1DT